Company / FCF Margin
Tarsus Pharmaceuticals, Inc. FCF Margin History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-4.9%
FY2025
5-year range
-682.0% / 5.5%
FY2021-FY2025
Trend
+89.3%
vs FY2024
Sector context
#67 of 134
Health Care
What the data says
At -4.9%, Tarsus Pharmaceuticals, Inc.'s fcf margin ranks #67 of 134 in the Health Care sector. Improved from -682.0% to -4.9% over the past 2 years.
Based on SEC 10-K filings.
-4.9% in FY2025 with a 3-year CAGR of -10.5%.
Improved from -682.0% to -4.9% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- -10.5pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
#67 of 134 in Health CareTop 50% of 134This company -4.9% Sector average -637.8%
▼
+99.2% above sector average
Key checks
Key Insights
- In FY2025, fcf margin increased 89.3% year-over-year.
- Currently 632.8pp above the Health Care sector average.
- Peak fcf margin was recorded in FY2022.
- Lowest fcf margin in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -4.9% | +89.3% |
| FY2024 | -46.2% | +93.2% |
| FY2023 | -682.0% | -12411.2% |
| FY2022 | 5.5% | +0.0% |
| FY2021 | 5.5% | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026